Department of Internal Medicine, University of Virginia Health, Charlottesville, VA, USA.
Department of Pharmacy, University of Virginia Health, Charlottesville, VA, USA.
Ann Card Anaesth. 2022 Jul-Sep;25(3):359-361. doi: 10.4103/aca.aca_98_21.
Catecholamine-resistant postoperative vasoplegic syndrome (PVS) lacks effective treatment modalities. Synthetic angiotensin II was recently approved for the treatment of vasodilatory shock; however, its use in PVS is not well described. We report outcomes in six patients receiving angiotensin II for the treatment of isolated PVS. All patients achieved their MAP goal and the majority showed improvement in lactate and background catecholamine dose; however, variables of perfusion changed discordantly. Three of six patients survived to hospital discharge.
儿茶酚胺抵抗性术后血管麻痹综合征（PVS）缺乏有效的治疗方法。合成血管紧张素 II 最近被批准用于治疗血管扩张性休克；然而，其在 PVS 中的应用尚未得到很好的描述。我们报告了 6 例接受血管紧张素 II 治疗孤立性 PVS 的患者的结局。所有患者均达到了 MAP 目标，大多数患者的乳酸和背景儿茶酚胺剂量有所改善；然而，灌注变量的变化不一致。6 例患者中有 3 例存活至出院。
